CL2022002843A1 - Pirfenidona para el tratamiento del coronavirus - Google Patents

Pirfenidona para el tratamiento del coronavirus

Info

Publication number
CL2022002843A1
CL2022002843A1 CL2022002843A CL2022002843A CL2022002843A1 CL 2022002843 A1 CL2022002843 A1 CL 2022002843A1 CL 2022002843 A CL2022002843 A CL 2022002843A CL 2022002843 A CL2022002843 A CL 2022002843A CL 2022002843 A1 CL2022002843 A1 CL 2022002843A1
Authority
CL
Chile
Prior art keywords
pirfenidone
subject
covid
cov
virus
Prior art date
Application number
CL2022002843A
Other languages
English (en)
Spanish (es)
Inventor
Aguilar-Cordova Estuardo
Aguilar Laura
Agustín Rogelio Magaña Castro José
Original Assignee
Excalibur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excalibur Pharmaceuticals Inc filed Critical Excalibur Pharmaceuticals Inc
Publication of CL2022002843A1 publication Critical patent/CL2022002843A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
CL2022002843A 2020-04-14 2022-10-14 Pirfenidona para el tratamiento del coronavirus CL2022002843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14

Publications (1)

Publication Number Publication Date
CL2022002843A1 true CL2022002843A1 (es) 2023-09-01

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002843A CL2022002843A1 (es) 2020-04-14 2022-10-14 Pirfenidona para el tratamiento del coronavirus

Country Status (14)

Country Link
US (1) US20230117397A1 (enExample)
EP (1) EP4135671A4 (enExample)
JP (1) JP2023521887A (enExample)
KR (1) KR20230038644A (enExample)
CN (1) CN115916162A (enExample)
AU (1) AU2021254765A1 (enExample)
BR (1) BR112022020821A2 (enExample)
CA (1) CA3175526A1 (enExample)
CL (1) CL2022002843A1 (enExample)
CO (1) CO2022016155A2 (enExample)
EC (1) ECSP22087664A (enExample)
IL (1) IL297296A (enExample)
MX (1) MX2022012986A (enExample)
WO (1) WO2021211745A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2003030720A2 (en) * 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
US20070072181A1 (en) * 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
SG176053A1 (en) * 2009-05-15 2011-12-29 Intermune Inc Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EP4491180A1 (en) * 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof

Also Published As

Publication number Publication date
CA3175526A1 (en) 2021-10-21
US20230117397A1 (en) 2023-04-20
EP4135671A1 (en) 2023-02-22
IL297296A (en) 2022-12-01
EP4135671A4 (en) 2024-08-14
WO2021211745A1 (en) 2021-10-21
BR112022020821A2 (pt) 2022-12-20
MX2022012986A (es) 2023-03-21
ECSP22087664A (es) 2022-12-30
AU2021254765A1 (en) 2022-12-08
KR20230038644A (ko) 2023-03-21
JP2023521887A (ja) 2023-05-25
CO2022016155A2 (es) 2022-12-20
CN115916162A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
CO2022016155A2 (es) Pirfenidona para el tratamiento del coronavirus
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
Malakar et al. Drug repurposing of quinine as antiviral against dengue virus infection
Farias et al. Chloroquine interferes with dengue‐2 virus replication in U937 cells
CL2020000685A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de estos.
Konwar et al. Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection
BR112012018529A2 (pt) inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
ECSP077252A (es) Métodos para tratar la hepatitis C
PH12015502230A1 (en) Novel viral replication inhibitors
EA201300135A1 (ru) Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
US12383585B2 (en) Methods of treatment of infections using bacteria
Jain et al. Role of intracellular events in the pathogenesis of dengue; an overview
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
ECSP21067052A (es) Formulación sólida del modulador de ensamblaje de la cápside
CU20200081A7 (es) Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
BR112021021454A2 (pt) Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
Singh¹ Role of Immunity Against COVID-19
US20230106048A1 (en) Method for treating dengue virus infection
Habibian et al. SARS-CoV-2 and Manipulating the Immune System